Auranofin attenuates TOPBP1-mediated ATR replication stress response and improves chemotherapeutic response in breast tumor models
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci180106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Shuai Ma und 19 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Breast Cancer Prevention and Therapy (Ministry of Education), National Key Laboratory of Blood Science, Key Laboratory of Immune Mi…. Hauptthemen laut MEDLINE: Auranofin, Breast Neoplasms, Ataxia Telangiectasia Mutated Proteins, DNA Replication. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, the National Key Research and Development Program of China, Tianjin Key Medical Discipline Construction Project.
Abstract (Originalsprache)
Genome instability is most commonly caused by replication stress, which also renders cancer cells extremely vulnerable once their response to replication stress is impeded. Topoisomerase II binding protein 1 (TOPBP1), an allosteric activator of ataxia telangiectasia and Rad3-related kinase (ATR), coordinates ATR in replication stress response and has emerged as a potential therapeutic target for tumors. Here, we identify auranofin, the FDA-approved drug for rheumatoid arthritis, as a lead compound capable of binding to the BRCT 7–8 domains and blocking TOPBP1 interaction with PHF8 and FANCJ. The liquid-liquid phase separation of TOPBP1 is also disrupted by auranofin. Through targeting these TOPBP1-nucleated molecular machineries, auranofin leads to an accumulation of replication defects by impairing ATR activation and attenuating replication protein A loading on perturbed replication forks, and it shows significant anti–breast tumor activity in combination with a PARP inhibitor. This study provides mechanistic insights into how auranofin challenges replication integrity and expands the application of this FDA-approved drug in breast tumor intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Breast Cancer Prevention and Therapy (Ministry of Education), National Key Laboratory of Blood Science, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and M…
- Center for Reproduction and Genetics, Department of Obstetrics and Gynecology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, USTC, Hefei,…
- Core Facilities Center, Capital Medical University, Beijing, China.
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin, China.
- Breast Surgery, The First Affiliated Hospital of China Medical University, Liaoning, China.
Förderung
- the National Natural Science Foundation of China
- the National Key Research and Development Program of China
- Tianjin Key Medical Discipline Construction Project
Zitieren
APA
Ma, S., Han, Y., Gu, R., Chen, Q., Guo, Q., Yue, Y., Cao, C., Liu, L., Yang, Z., Qin, Y., Yang, Y., Zhang, K., Liu, F., Liu, L., Yang, N., Hao, J., Yang, J., Yao, Z., Mao, X., & Shi, L. (2025). Auranofin attenuates TOPBP1-mediated ATR replication stress response and improves chemotherapeutic response in breast tumor models. Journal of Clinical Investigation. https://doi.org/10.1172/jci180106
Vancouver
Ma S, Han Y, Gu R, Chen Q, Guo Q, Yue Y, et al. Auranofin attenuates TOPBP1-mediated ATR replication stress response and improves chemotherapeutic response in breast tumor models. Journal of Clinical Investigation. 2025. doi:10.1172/jci180106
BibTeX
@article{Ma2025,
author = {Ma, Shuai and Han, Yingying and Gu, Rui and Chen, Qi and Guo, Qiushi and Yue, Yuan and Cao, Cheng and Liu, Ling and Yang, Zhenzhen and Qin, Yan and Yang, Ying and Zhang, Kai and Liu, Fei and Liu, Lin and Yang, Na and Hao, Jihui and Yang, Jie and Yao, Zhi and Mao, Xiaoyun and Shi, Lei},
title = {Auranofin attenuates TOPBP1-mediated ATR replication stress response and improves chemotherapeutic response in breast tumor models},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci180106}
}
EUVIMED